Effective treatment of topical corticosteroid‐resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome

The Journal of DermatologyEarly View LETTER TO THE EDITOR Effective treatment of topical corticosteroid-resistant dermatitis with delgocitinib in a pediatric patient with Netherton syndrome Marina Teraoka, Marina Teraoka Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorSatoru Yonekura, Satoru Yonekura orcid.org/0000-0003-4047-3016 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorTomoya Takegami, Tomoya Takegami Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorTeruasa Murata, Teruasa Murata orcid.org/0000-0001-8350-1289 Department of Dermatology, Hyogo Medical University, Hyogo, JapanSearch for more papers by this authorGyohei Egawa, Gyohei Egawa orcid.org/0000-0002-6101-4719 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorSaeko Nakajima, Corresponding Author Saeko Nakajima [email protected] orcid.org/0000-0003-0831-1447 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan Correspondence Saeko Nakajima, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Email: [email protected]Search for more papers by this authorKenji Kabashima, Kenji Kabashima [email protected] orcid.org/0000-0002-0773-0554 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, SingaporeSearch for more papers by this author Marina Teraoka, Marina Teraoka Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorSatoru Yonekura, Satoru Yonekura orcid.org/0000-0003-4047-3016 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorTomoya Takegami, Tomoya Takegami Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorTeruasa Murata, Teruasa Murata orcid.org/0000-0001-8350-1289 Department of Dermatology, Hyogo Medical University, Hyogo, JapanSearch for more papers by this authorGyohei Egawa, Gyohei Egawa orcid.org/0000-0002-6101-4719 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanSearch for more papers by this authorSaeko Nakajima, Corresponding Author Saeko Nakajima [email protected] orcid.org/0000-0003-0831-1447 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan Department of Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan Correspondence Saeko Nakajima, Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Email: [email protected]Search for more papers by this authorKenji Kabashima, Kenji Kabashima [email protected] orcid.org/0000-0002-0773-0554 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore Skin Research Institute of Singapore (SRIS), Agency for Science, Technology and Research (A*STAR), Singapore, SingaporeSearch for more papers by this author First published: 28 May 2024 https://doi.org/10.1111/1346-8138.17311Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Barbati F, Giovannini M, Oranges T, Lodi L, Barni S, Novembre E, et al. Netherton syndrome in children: management and future perspectives. Front Pediatr. 2021; 9:645259. 10.3389/fped.2021.645259 PubMedWeb of Science®Google Scholar 2Zheng CC, Chen XX, Zou RT, Cai GY, Chen RY. Treatment of Netherton syndrome with abrocitinib. JAMA Dermatol. 2023; 159: 791–793. 10.1001/jamadermatol.2023.0561 PubMedGoogle Scholar 3Dodeja A, Meshram K, Pande S, Oke M, Borkar M. Oral tofacitinib therapy for the effective management of Netherton syndrome. Cureus. 2023; 15:e39349. PubMedGoogle Scholar 4Anagawa-Nakamura A, Ryoke K, Yasui Y, Shoda T, Sugai S. Effects of delgocitinib ointment 0.5% on the normal mouse skin and epidermal tight junction proteins in comparison with topical corticosteroids. Toxicol Pathol. 2020; 48: 1008–1016. 10.1177/0192623320970896 CASPubMedWeb of Science®Google Scholar 5Abe M, Iizuka H, Nemoto-Hasebe I, Nemoto O, Toyama H, Ohashi-Doi K, et al. Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function. J Cutan Immunol Allergy. 2022; 5: 38–46. 10.1002/cia2.12213 Web of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation